JPS6257606B2 - - Google Patents
Info
- Publication number
- JPS6257606B2 JPS6257606B2 JP53147345A JP14734578A JPS6257606B2 JP S6257606 B2 JPS6257606 B2 JP S6257606B2 JP 53147345 A JP53147345 A JP 53147345A JP 14734578 A JP14734578 A JP 14734578A JP S6257606 B2 JPS6257606 B2 JP S6257606B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- piperidyl
- indolyl
- compound
- urea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 30
- 125000005936 piperidyl group Chemical group 0.000 claims description 29
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 22
- 239000004202 carbamide Substances 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000001041 indolyl group Chemical group 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 229910052717 sulfur Chemical group 0.000 claims description 3
- 239000011593 sulfur Chemical group 0.000 claims description 3
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 66
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 22
- 238000004519 manufacturing process Methods 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000002844 melting Methods 0.000 description 11
- 230000008018 melting Effects 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 6
- 231100000111 LD50 Toxicity 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 6
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 6
- 230000003276 anti-hypertensive effect Effects 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000007429 general method Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229960002748 norepinephrine Drugs 0.000 description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- -1 ethoxy, propoxy Chemical group 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- VDPTZNWSWWZWNC-UHFFFAOYSA-N n-(piperidin-4-ylcarbamoyl)benzamide Chemical compound C=1C=CC=CC=1C(=O)NC(=O)NC1CCNCC1 VDPTZNWSWWZWNC-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229910052722 tritium Inorganic materials 0.000 description 3
- BHNHHSOHWZKFOX-UHFFFAOYSA-N 2-methyl-1H-indole Chemical compound C1=CC=C2NC(C)=CC2=C1 BHNHHSOHWZKFOX-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010054089 Depressive symptom Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 229960004801 imipramine Drugs 0.000 description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000012154 norepinephrine uptake Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000013275 serotonin uptake Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- GMTDTFQBVHLRCF-UHFFFAOYSA-N 4-fluoro-n-(piperidin-4-ylcarbamoyl)benzamide Chemical compound C1=CC(F)=CC=C1C(=O)NC(=O)NC1CCNCC1 GMTDTFQBVHLRCF-UHFFFAOYSA-N 0.000 description 1
- OLKFDXNJEKJUPQ-UHFFFAOYSA-N 4-methoxy-n-(piperidin-4-ylcarbamoyl)benzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC(=O)NC1CCNCC1 OLKFDXNJEKJUPQ-UHFFFAOYSA-N 0.000 description 1
- LMIQERWZRIFWNZ-UHFFFAOYSA-N 5-hydroxyindole Chemical compound OC1=CC=C2NC=CC2=C1 LMIQERWZRIFWNZ-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- DWAQDRSOVMLGRQ-UHFFFAOYSA-N 5-methoxyindole Chemical compound COC1=CC=C2NC=CC2=C1 DWAQDRSOVMLGRQ-UHFFFAOYSA-N 0.000 description 1
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 206010027646 Miosis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- SNIXRMIHFOIVBB-UHFFFAOYSA-N N-Hydroxyl-tryptamine Chemical compound C1=CC=C2C(CCNO)=CNC2=C1 SNIXRMIHFOIVBB-UHFFFAOYSA-N 0.000 description 1
- HRYILSDLIGTCOP-UHFFFAOYSA-N N-benzoylurea Chemical compound NC(=O)NC(=O)C1=CC=CC=C1 HRYILSDLIGTCOP-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical group 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000020335 dealkylation Effects 0.000 description 1
- 238000006900 dealkylation reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229960004486 desoxycorticosterone acetate Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000008396 flotation agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- UXKUODQYLDZXDL-UHFFFAOYSA-N fulminic acid Chemical compound [O-][N+]#C UXKUODQYLDZXDL-UHFFFAOYSA-N 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- VMISGTWVIOPFHG-UHFFFAOYSA-N n-(piperidin-4-ylcarbamoyl)thiophene-2-carboxamide Chemical compound C=1C=CSC=1C(=O)NC(=O)NC1CCNCC1 VMISGTWVIOPFHG-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 230000003982 neuronal uptake Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 230000036967 uncompetitive effect Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB50053/77A GB1586817A (en) | 1977-12-01 | 1977-12-01 | Indole derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5585586A JPS5585586A (en) | 1980-06-27 |
JPS6257606B2 true JPS6257606B2 (US06197789-20010306-C00002.png) | 1987-12-02 |
Family
ID=10454471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP14734578A Granted JPS5585586A (en) | 1977-12-01 | 1978-11-30 | Novel indole compound |
Country Status (20)
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL135545B1 (en) * | 1980-03-01 | 1985-11-30 | Wyeth John & Brother Ltd | Process for preparing novel derivatives of piperidine |
US4806552A (en) * | 1980-03-01 | 1989-02-21 | John Wyeth & Brother, Limited | Pyridyl- and/or pyridoyl-(piperid-4-yl) ureas and analogues thereof |
US4722930A (en) * | 1980-03-01 | 1988-02-02 | John Wyeth And Brother Limited | 3-benzoyl-1-[(oxo or thioheteroaryl-ylalkyl)-piperid-4-yl]ureas and derivatives |
US4808601A (en) * | 1984-09-19 | 1989-02-28 | Pfizer Inc. | Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds |
US4752609A (en) * | 1985-06-20 | 1988-06-21 | Pfizer Inc. | Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds |
GB8528234D0 (en) * | 1985-11-15 | 1985-12-18 | Wyeth John & Brother Ltd | Heterocyclic compounds |
CN1798557A (zh) * | 2003-05-29 | 2006-07-05 | 协和梅迪克斯株式会社 | 抗抑郁剂或者抗抑郁用饮食品 |
AR070398A1 (es) * | 2008-02-22 | 2010-03-31 | Gruenenthal Chemie | Derivados sustituidos de indol |
MX2020004842A (es) * | 2017-11-03 | 2020-10-16 | Bioimics Ab | Compuestos heterociclicos antiinfecciosos y sus usos. |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4061641A (en) * | 1973-10-10 | 1977-12-06 | John Wyeth & Brother Limited | Ureidopiperidino-ketoalkyl indoles |
GB1425354A (en) * | 1973-10-10 | 1976-02-18 | Wyeth John & Brother Ltd | Indole derivatives |
GB1494805A (en) * | 1975-07-17 | 1977-12-14 | Wyeth John & Brother Ltd | Indole derivatives |
ZA76475B (en) * | 1975-03-10 | 1977-08-31 | Ciba Geigy Ag | Indolyalkylpiperidines |
-
1977
- 1977-12-01 GB GB50053/77A patent/GB1586817A/en not_active Expired
-
1978
- 1978-10-24 IE IE2100/78A patent/IE47461B1/en unknown
- 1978-10-26 ZA ZA786058A patent/ZA786058B/xx unknown
- 1978-10-30 NZ NZ188773A patent/NZ188773A/xx unknown
- 1978-11-01 AU AU41231/78A patent/AU516185B2/en not_active Expired
- 1978-11-07 CA CA315,936A patent/CA1093558A/en not_active Expired
- 1978-11-08 US US05/958,763 patent/US4209521A/en not_active Expired - Lifetime
- 1978-11-14 FI FI783473A patent/FI783473A/fi unknown
- 1978-11-17 DK DK513678A patent/DK513678A/da not_active Application Discontinuation
- 1978-11-20 PH PH21825A patent/PH19933A/en unknown
- 1978-11-21 EP EP78300651A patent/EP0002886B1/en not_active Expired
- 1978-11-21 DE DE7878300651T patent/DE2861179D1/de not_active Expired
- 1978-11-23 IT IT30109/78A patent/IT1100596B/it active
- 1978-11-28 YU YU02803/78A patent/YU280378A/xx unknown
- 1978-11-29 SU SU782692750A patent/SU1042612A3/ru active
- 1978-11-29 HU HU78WI297A patent/HU179361B/hu unknown
- 1978-11-29 AT AT0853578A patent/AT365591B/de not_active IP Right Cessation
- 1978-11-30 PT PT68850A patent/PT68850A/pt unknown
- 1978-11-30 ES ES475565A patent/ES475565A1/es not_active Expired
- 1978-11-30 JP JP14734578A patent/JPS5585586A/ja active Granted
-
1979
- 1979-05-16 ES ES480603A patent/ES480603A1/es not_active Expired
- 1979-05-16 ES ES480604A patent/ES480604A1/es not_active Expired
- 1979-05-16 ES ES480602A patent/ES480602A1/es not_active Expired
- 1979-12-18 SU SU792852306A patent/SU1087073A3/ru active
-
1980
- 1980-01-04 SU SU802862505A patent/SU1110380A3/ru active
- 1980-01-07 SU SU802864113A patent/SU1083910A3/ru active
Also Published As
Publication number | Publication date |
---|---|
DE2861179D1 (en) | 1981-12-24 |
IT7830109A0 (it) | 1978-11-23 |
EP0002886A2 (en) | 1979-07-11 |
PH19933A (en) | 1986-08-14 |
HU179361B (en) | 1982-10-28 |
SU1042612A3 (ru) | 1983-09-15 |
FI783473A (fi) | 1979-06-02 |
SU1083910A3 (ru) | 1984-03-30 |
PT68850A (en) | 1978-12-01 |
ES480604A1 (es) | 1980-04-01 |
GB1586817A (en) | 1981-03-25 |
YU280378A (en) | 1983-01-21 |
DK513678A (da) | 1979-06-02 |
ZA786058B (en) | 1980-05-28 |
ES475565A1 (es) | 1980-01-16 |
US4209521A (en) | 1980-06-24 |
EP0002886A3 (en) | 1979-07-25 |
NZ188773A (en) | 1981-03-16 |
AT365591B (de) | 1982-01-25 |
ATA853578A (de) | 1981-06-15 |
ES480602A1 (es) | 1980-04-01 |
IE47461B1 (en) | 1984-03-21 |
AU4123178A (en) | 1979-06-07 |
SU1110380A3 (ru) | 1984-08-23 |
IT1100596B (it) | 1985-09-28 |
EP0002886B1 (en) | 1981-10-14 |
JPS5585586A (en) | 1980-06-27 |
AU516185B2 (en) | 1981-05-21 |
ES480603A1 (es) | 1980-04-01 |
IE782100L (en) | 1979-06-01 |
CA1093558A (en) | 1981-01-13 |
SU1087073A3 (ru) | 1984-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR850000630B1 (ko) | 피페리딘 유도체의 제조방법 | |
BG100040A (bg) | Индолови производни като 5-нт1а и/или 5-нт2 лиганди | |
EP1988076A1 (en) | Amide derivative or salt thereof | |
JPH05508660A (ja) | ジアリールメチルピペリジンまたはピペラジンのピリジンおよびピリジンn−オキシド誘導体、並びにそれらの組成物および使用方法 | |
WO1996003400A1 (en) | 4-indole derivatives as serotonin agonists and antagonists | |
CZ20031941A3 (cs) | Substituované triazol diaminové deriváty jako inhibitory kináz | |
EP0699194B1 (en) | 5-ht4 receptor antagonists | |
JPH09511503A (ja) | 中枢神経系薬剤としてのナフチルアミド | |
JP3047470B2 (ja) | 中枢神経系剤としての置換されたテトラヒドロピリジンおよびヒドロキシピペリジン | |
TW200425894A (en) | Treatment of psychotic and depressive disorders | |
WO1994021627A1 (en) | Indole derivatives as dopamine d4 antagonists | |
JPH04235164A (ja) | 3−アリールカルボニル−1−アミノアルキル−1h−インドール含有抗緑内障組成物 | |
JPS6257606B2 (US06197789-20010306-C00002.png) | ||
JP3883567B2 (ja) | N置換アザビシクロヘプタン誘導体、例えば神経弛緩剤 | |
KR100196985B1 (ko) | 피페리딘 유도체 | |
JP2001512111A (ja) | 下部尿路に作用するピペラジン誘導体 | |
DE69215482T2 (de) | 2,2'-Alkylendiindolderivate, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und deren Verwendung als Ulcustherapeutikum | |
JP4018145B2 (ja) | α2―アドレナリン受容体アゴニスト活性を有する4―[(チエン―2―イル)メチル]イミダゾール誘導体 | |
DE69526509T2 (de) | Von indol abgeleitete aromatische ether als "5ht1-like" liganden | |
KR20010031297A (ko) | 2-치환된 1,2-벤즈이소티아졸 유도체 및 세로토닌 길항제(5-ht1a, 5-ht1b 및 5-ht1d)로서의 그의 용도 | |
JPH0377191B2 (US06197789-20010306-C00002.png) | ||
JPH07502273A (ja) | ベンゾピラン クラス3抗不整脈薬 | |
JPH0723372B2 (ja) | 複素環式化合物 | |
JP2002513016A (ja) | セロトニン作動薬としてのインドリル誘導体 | |
JPS6157582A (ja) | 新規なベンゾジアゼピン類 |